image credit- freepik
China-based MediLink Therapeutics has entered into a new collaboration and exclusive licensing agreement with Roche for the development and commercialisation of YL201, an investigational novel antibody-drug conjugate (ADC) asset targeting B7H3 across numerous solid tumour types.
Under the terms of the agreement, MediLink will grant Roche an exclusive license to develop, manufacture, and commercialise YL201 worldwide, excluding the mainland of China, the Hong Kong Special Administrative Region, and the Macau Special Administrative Region.
MediLink will receive upfront and near-term milestone payments of $570 million, together with additional development, regulatory, and commercial milestone payments, as well as tiered royalties on net sales of YL201 outside of China, once approved.
This new agreement for YL201 builds on the successful collaboration initiated in January 2024 for the YL211 (c-Met ADC) program. MediLink and Roche are now deepening their collaboration through the development of YL201. Through this new agreement, the two companies will leverage their complementary strengths to accelerate YL201's path to global regulatory approvals. United by a shared commitment to scientific innovation and patient benefit, MediLink and Roche strive to bring this potentially transformative therapy option quickly to patients.
